Related Experiment Video
Updated: Jun 19, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Revolutionizing Cancer Treatment: Unleashing the Power of Combining Oncolytic Viruses with CAR-T Cells
Lin Zhang1, ShuXian Guo1, ShuYing Chang1
1Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China.
Abstract:
Oncolytic Viruses (OVs) have emerged as a promising treatment option for cancer thanks to their significant research potential and encouraging results. These viruses exert a profound impact on the tumor microenvironment, making them effective against various types of cancer. In contrast, the efficacy of Chimeric antigen receptor (CAR)-T cell therapy in treating solid tumors is relatively low. The combination of OVs and CAR-T cell therapy, however, is a promising area of research. OVs play a crucial role in enhancing the tumor-suppressive microenvironment, which in turn enables CAR-T cells to function efficiently in the context of solid malignancies. This review aims to provide a comprehensive analysis of the benefits and drawbacks of OV therapy and CAR-T cell therapy, with a focus on the potential of combining these two treatment approaches.
Insights
Oncolytic viruses (OVs) and Chimeric antigen receptor (CAR)-T cell therapy show promise for cancer treatment. Combining OVs with CAR-T cells may enhance efficacy against solid tumors by improving the tumor microenvironment.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Oncolytic viruses (OVs) are emerging as potent cancer therapeutics due to their ability to modify the tumor microenvironment.
- Chimeric antigen receptor (CAR)-T cell therapy demonstrates limited efficacy in solid tumors.
- The tumor microenvironment significantly influences the effectiveness of cancer immunotherapies.
Purpose of the Study:
- To review the benefits and drawbacks of Oncolytic Virus (OV) therapy.
- To review the benefits and drawbacks of Chimeric antigen receptor (CAR)-T cell therapy.
- To analyze the potential of combining OV and CAR-T cell therapies for solid tumors.
Main Methods:
- Literature review of OV therapy.
- Literature review of CAR-T cell therapy.
- Analysis of combined OV and CAR-T cell therapy strategies.
Main Results:
- OVs effectively impact the tumor microenvironment, showing promise across various cancers.
- CAR-T cell therapy faces challenges in solid tumor treatment.
- OVs can enhance the tumor microenvironment, potentially improving CAR-T cell function in solid tumors.
Conclusions:
- OV therapy offers significant potential for cancer treatment.
- Combining OVs with CAR-T cells presents a promising strategy to overcome limitations in solid tumor immunotherapy.
- Further research into combined OV and CAR-T cell approaches is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...